Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 20;13:874108. doi: 10.3389/fimmu.2022.874108

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Alexandre, Bohelay, Gille, Le Roux-Villet, Soued, Morin, Caux, Grootenboer-Mignot and Prost-Squarcioni

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Clinical and laboratory variables during the first year after omalizumab therapy in the 13 patients. Individual values through time on a linear scale (black: remittent patients, red: non–remittent patients): (A) Daily blister count, (B) Pruritus visual analogic score, (C) Urticaria score, (D) Eosinophil count, (E) BP180–NC16A IgG level, (F) BP180–NC16A IgE level over time for the 8 patients with measurable IgE auto–antibodies during follow–up, (G) Log–2 scale evolution of the mean values over time of eosinophil blood count, daily blister count, pruritus visual analogic score, and BP180–NC16A IgG.